Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition

(2017) Stephanie Lheureux et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

(2017) Nikolas Herold et al.   NATURE MEDICINE

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

(2017) Olga Kondrashova et al.   Cancer Discovery

Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance

(2017) Rachel W Anantha et al.   eLife

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells

(2016) Ruoxi Hong et al.   BMC CANCER

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

(2016) A. Lester et al.   Clinical & Translational Oncology

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

(2016) Aiste McCormick et al.   CLINICAL CANCER RESEARCH

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma

(2016) Mariam M. AlHilli et al.   GYNECOLOGIC ONCOLOGY

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

(2016) Rinske Drost et al.   JOURNAL OF CLINICAL INVESTIGATION

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

(2016) Ying-Qing Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44

(2016) Jun-Mei Yi et al.   MOLECULAR CANCER THERAPEUTICS

Replication fork stability confers chemoresistance in BRCA-deficient cells

(2016) Arnab Ray Chaudhuri et al.   NATURE

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

(2016) Constanze Schneider et al.   NATURE MEDICINE

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

(2016) Mansoor R. Mirza et al.   NEW ENGLAND JOURNAL OF MEDICINE

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers

(2015) Chong-kui Sun et al.   Oncotarget

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma

(2015) Jara Majuelos-Melguizo et al.   Oncotarget

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors

(2013) Na Ye et al.   JOURNAL OF MEDICINAL CHEMISTRY

Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo

(2013) D. M. Janzen et al.   MOLECULAR CANCER THERAPEUTICS

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

(2013) N. Johnson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes

(2012) Kathryn P. Pennington et al.   GYNECOLOGIC ONCOLOGY

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics

(2010) Jin-xue He et al.   ACTA PHARMACOLOGICA SINICA

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

(2010) K. J. Dedes et al.   Science Translational Medicine

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE